AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks

NORTH CHICAGO Ill. Feb. 16 2018 PRNewswire AbbVie NYSE ABBV a global research and developmentbased biopharmaceutical company today announced new results from the doubleblinded extension phase of the Phase 2 CELEST study showing that...